By John Carroll
Shares of Vical got a boost on Tuesday after the developer said its swine flu jab sailed through an animal study with positive results. Its stock shot up 20 percent on the news that the vaccine is ready for a human study--marching into the clinic in record time.
All the rabbits and mice injected with the H1N1 vaccine were protected in the preclinical study and three out of four hit a key protection mark after a single dose. Those were the numbers Vical needed to get a human study underway, and the company says it's ready to start large scale manufacturing needed to produce a vaccine for clinical trials.
Researchers at a long lineup of vaccine developers have been racing to get a new flu vaccine ready for mass production in anticipation that the worldwide demand for a new jab is likely to be immense. It took Vical only two months to take a swine flu sample and jump ahead to a clinical trial.
"These results provide additional validation for Vical's technology platform, demonstrating not only efficacy and but also speed in generating a vaccine to an influenza strain that emerged in April 2009," wrote Rodman & Renshaw analyst Reni Benjamin.
- check out the story from Forbes
Vical raises $20M for vaccine programs
Vical raises $15.4M in RDO
U.S. budgets $1B to fuel swine flu research
Glaxo fields big H1N1 vax orders as Vical starts testing